Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer.


Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 14 02 2020
revised: 14 05 2020
accepted: 28 05 2020
pubmed: 6 6 2020
medline: 26 5 2021
entrez: 6 6 2020
Statut: ppublish

Résumé

At present, the overall sensitivity and specificity of blood biomarkers are insufficient for a diagnosis of colorectal cancer (CRC). We analyzed the serum synaptophysin like 1 (sSYPL1) in controls, adenoma patients, CRC patients, pre- and postoperative CRC patients by ELISA. The upregulation of SYPL1 was confirmed in CRC tissues at both mRNA and protein levels. Consistently, sSYPL1 was significantly higher in CRC patients than in either controls (t = 14.50, P < 0.0001) or adenoma patients (t = 10.56, P < 0.0001) and was associated with lymph node invasion (χ sSYPL1 might be an outstanding marker for CRC diagnosis, especially for patients with low CEA levels.

Sections du résumé

BACKGROUND BACKGROUND
At present, the overall sensitivity and specificity of blood biomarkers are insufficient for a diagnosis of colorectal cancer (CRC).
METHODS METHODS
We analyzed the serum synaptophysin like 1 (sSYPL1) in controls, adenoma patients, CRC patients, pre- and postoperative CRC patients by ELISA.
RESULTS RESULTS
The upregulation of SYPL1 was confirmed in CRC tissues at both mRNA and protein levels. Consistently, sSYPL1 was significantly higher in CRC patients than in either controls (t = 14.50, P < 0.0001) or adenoma patients (t = 10.56, P < 0.0001) and was associated with lymph node invasion (χ
CONCLUSION CONCLUSIONS
sSYPL1 might be an outstanding marker for CRC diagnosis, especially for patients with low CEA levels.

Identifiants

pubmed: 32502495
pii: S0009-8981(20)30262-X
doi: 10.1016/j.cca.2020.05.048
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
CA-19-9 Antigen 0
Carcinoembryonic Antigen 0
Synaptophysin 0
SYPL1 protein, human 159447-27-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-42

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lei Liu (L)

Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.

Qiao He (Q)

Department of Clinical Laboratory, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610031, China.

Yan Li (Y)

Department of General Surgery, No. 42 Hospital of PLA, Leshan, Sichuan 614000, China.

Bing Zhang (B)

Department of Clinical Laboratory, Nanchong Central Hospital, Nanchong, Sichuan 637000, China.

Xiaobin Sun (X)

Department of Gastroenterology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.

Jing Shan (J)

Department of Gastroenterology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.

Biran Pan (B)

Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.

Tongtong Zhang (T)

Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.

Zihao Zhao (Z)

Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.

Xiaoyu Song (X)

Department of Clinical Laboratory, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610031, China. Electronic address: 913775584@qq.com.

Yuanbiao Guo (Y)

Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China. Electronic address: guo.ybiao@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH